Skip to main content
SpringerLink
Log in

Gilead's Sovaldi (sofosbuvir) the market leader in HCV

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Decision Resources Group. While Gilead's Sovaldi Continues to Dominate the Hepatitis C Space, Janssen's Olysio Has Gained Market Share Driven by Off-label Prescribing. Media Release : 19 May 2014

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gilead's Sovaldi (sofosbuvir) the market leader in HCV. PharmacoEcon Outcomes News 704, 9 (2014). https://doi.org/10.1007/s40274-014-1294-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1294-0

Search

Navigation